Generated by AI
Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases. Biogen’s current portfolio includes treatments for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis, and Friedreich’s ataxia, along with therapies and biosimilars used in specialized immunology and related areas. The company also advances medicines through its research and development programs, with a strong emphasis on neuroscience and immunology. Based in Cambridge, Massachusetts, Biogen serves patients and healthcare providers across multiple global markets through its commercial products and collaborations. Its role in the financial market is shaped by its concentration in specialty biopharmaceuticals, recurring demand for chronic-disease treatments, and continued activity in pipeline development and product commercialization.
Website225 Binney Street
Cambridge, MA, 02142
United States
The latest articles about BIIB.
Summary of Oct 29's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Summary of Oct 12's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about BIIB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.